Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714180 · ClinicalTrials.gov registry record
Effect of Body Mass on Acyclovir Pharmacokinetics
A clinical trial of Hematological Malignancy and Pharmacokinetics of Acyclovir, sponsored by West Virginia University.
- Completed
- Registry status
- 14
- Enrollment target
- 1
- Study location
NCT01714180: Completed study of Hematological Malignancy and Pharmacokinetics of Acyclovir, sponsored by West Virginia University.
NCT01714180 is a study of Hematological Malignancy and Pharmacokinetics of Acyclovir that has completed, run by West Virginia University. The registered enrollment target is 14 participants, below the 120-participant average among 9 other Hematological Malignancy trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01714180, a study of Hematological Malignancy and Pharmacokinetics of Acyclovir, has completed, sponsored by West Virginia University.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking acyclovir to determine if higher body weights affect drug exposure. The information gathered from this study will help understand if patients with higher body weights need a different dosing plan. Patients receiving acyclovir as standard of care will be enrolled into this study. They will have blood draws once before they take acyclovir and 10 times after they take the acyclovir (over a total of 12 hours). These patients will be in the hospital already and will not need to make additional trips back to have blood drawn. A total of about 4-5 tablespoons of blood will be drawn for this study. 7 obese patients and 7 matched, non-obese patients will be enrolled into this study.
Conditions Studied
Study Locations (1)
West Virginia
- West Virginia University Hospitals Mary Babb Randolph Cancer Center - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-03 |
What the finished NCT01714180 record still lists
NCT01714180 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 120-participant average among 9 other Hematological Malignancy trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Hematological Malignancy appearing as the primary indexed condition, and to 0 interventions.
NCT01714180 reports a single indexed study location in West Virginia.
Frequently Asked Questions
What is clinical trial NCT01714180 about?
NCT01714180 is a clinical study titled "Effect of Body Mass on Acyclovir Pharmacokinetics". Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking acyclovir to determine if higher body weights affect drug exposure. The information gathered from this s...
What is the current status of trial NCT01714180?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2012-10. Estimated completion is 2015-03.
What conditions does trial NCT01714180 study?
This clinical trial studies the following conditions: Hematological Malignancy, Pharmacokinetics of Acyclovir.
Who is sponsoring clinical trial NCT01714180?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01714180 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01714180's enrollment target sits among peer trials
14 10th of 9 the lowest of 9 other Hematological Malignancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematological Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
RECRUITING · Phase 2
-
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
RECRUITING · Phase 2
-
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
RECRUITING
-
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
RECRUITING
-
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
RECRUITING · Phase 1
-
Membrane Target Detection for Leukemia Treatment
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia